Heart failure & cardiomyopathies
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma
Main finding · Anthracycline-based treatmentResult — go to the resultOdds ratio 0.55 95% CI 0.49–0.61Authors' conclusion
In this study, preexisting HF in patients with newly diagnosed DLBCL was common and was associated with lower use of anthracyclines and lower use of any chemotherapy.
Study context
- Population
- Individuals ≥65 years with newly diagnosed diffuse large B-cell lymphoma (DLBCL), 2000–2015, with continuous Medicare Part A or B in the prior year
- Participants
- 30,728 individuals
- Exposure
- Preexisting heart failure (HF) vs no preexisting HF
- Preexisting HFn = 4,266
- Outcome
- Anthracycline-based treatment
Methodological detailspopulation-based, SEER-Medicare registry
- Population-based
- SEER-Medicare registry
Main finding
As reported in the abstract
Odds ratio
0.55
95% CI 0.49–0.61
Preexisting HFvs Without preexisting HF
OR 0.55 (95% CI 0.49–0.61)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Preexisting HF | Without preexisting HF | HR (95% CI) | |
|---|---|---|---|---|
| Lymphoma mortality · 1 yearAdjusted for baseline and time-varying treatment factors | 41.8% (95% CI 40.5–43.2) | 29.6% (95% CI 29.0%–30.1%) | 1.24 (1.18–1.31) | |
| 0.512Hazard ratio (log scale) |
- Prevalence of preexisting HF at lymphoma diagnosis
- 13.9% · 4266
- Dexrazoxane or liposomal doxorubicin use (preexisting HF receiving an anthracycline)
- 7.0% · 78
Original publication
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. JAMA Cardiol. Published 1 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →